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Abstract
Iron deficiency, even in the absence of anemia, can be debilitating, and exacerbate any underlying
chronic disease, leading to increased morbidity and mortality. Iron deficiency is frequently concom-
itant with chronic inflammatory disease; however, iron deficiency treatment is often overlooked,
partially due to the heterogeneity among clinical practice guidelines. In the absence of consistent
guidance across chronic heart failure, chronic kidney disease and inflammatory bowel disease, we
provide practical recommendations for iron deficiency to treating physicians: definition, diagnosis,
and disease-specific diagnostic algorithms. These recommendations should facilitate appropriate
diagnosis and treatment of iron deficiency to improve quality of life and clinical outcomes.
“Iron deficiency is very common but often overlooked, especially in
people with chronic conditions. Iron deficiency is a health-related
condition in which iron availability is insufficient to meet the
body’s needs and, therefore, its timely detection and treatment is
important, because iron is essential to the functioning of all
organs”1
1 | INTRODUCTION
Managing patients with chronic diseases, particularly those with com-
plex inflammatory disorders, can be challenging. In these patients, a
considered multidisciplinary approach needs to be adopted to maintain
quality of life (QoL) and improve outcomes.2,3 One condition that is fre-
quently associated with chronic disease, but often overlooked, is iron
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deficiency. Iron deficiency is estimated to affect 37–61% of patients
with chronic heart failure (CHF), 24–85% of patients with chronic kid-
ney disease (CKD) and 13–90% of patients with inflammatory bowel
disease (IBD).4–9 Iron is essential to every cell and, while its fundamental
role in oxygen transport through erythropoiesis is well recognized, it is
equally critical for energy production and efficient functioning of all of
the body’s organs.10,11 In patients with chronic inflammatory conditions,
its impact can be particularly severe and may exacerbate the underlying
disease state, leading to accelerated clinical deterioration.5,12
Anemia is the ultimate consequence of iron deficiency in many
patients with chronic inflammatory conditions.2,3,13,14 However, the
medical field should recognize iron deficiency as a clinical condition dis-
tinct from anemia. Recognition is improving owing to our better under-
standing of the pathophysiological role of iron deficiency (independent
of chronic anemia) in symptomatology and clinical outcomes.10,15,16
This is further supported by recent clinical observations of an associa-
tion between the alleviation of morbidity or mortality and the treat-
ment of iron deficiency, even outside the context of anemia.6,17,18
However, there is uncertainty among physicians on how to diagnose
iron deficiency in patients with chronic inflammatory conditions. This is
partially because of symptom overlap with the underlying disease and
unclear laboratory diagnostic thresholds. Several publications have also
highlighted the problems of recognizing iron deficiency in the context
of anemia of inflammation.13,19–21 This has led to under-diagnosis of
an easily treatable condition, leading to anemia, at which point physi-
cians feel more confident about using iron therapy.22
In part, this uncertainty also stems from the heterogeneity of
guideline recommendations for the diagnosis and management of iron
deficiency in chronic inflammatory diseases. In the absence of any
overarching guidance, a series of roundtable discussions were con-
vened to try and bridge this gap. Our objectives were to: (1) provide a
definition of iron deficiency; (2) examine the current evidence on (and
identify knowledge gaps in the clinical impact of iron deficiency in
chronic inflammatory conditions, specifically CHF, CKD, and IBD; and
(3) provide practical guidance for the diagnosis of iron deficiency in
these patient populations.
1.1 | Mechanisms of iron deficiency in chronic
inflammation
Iron plays an important role in many physiological processes.15 All
aspects of iron homeostasis are tightly controlled and regulation of iron
transport is central to this process.10,23 The hepatic peptide hormone
hepcidin and its transmembrane receptor, ferroportin, control the princi-
pal routes of iron transport and availability in the body.15 Hepcidin levels
are feedback regulated by plasma iron concentration and the amount of
iron stores.15 Levels are also negatively regulated by the activity of
erythrocyte precursors, the main consumers of iron.15 Hepcidin controls
the internalization and degradation of ferroportin, which transfers cellu-
lar iron into the plasma and is predominantly expressed in key iron
exporters (eg, enterocytes and iron-recyclingmacrophages).10,16
Hepcidin, and therefore the regulation of ferroportin, is affected
by inflammation (Figure 1).15,24,25 In inflammatory conditions, hepcidin
production and release is induced by circulating proinflammatory
cytokines, especially interleukin-6. This results in increased internaliza-
tion and degradation of ferroportin and subsequent cellular iron reten-
tion. This ultimately leads to decreased levels of circulating iron, which
may result in insufficient iron availability to meet the body’s
needs.10,15,16
It is estimated that for the healthy individual, total body iron con-
tent is 3–4 g, of which 1–2 mg of exogenous iron is absorbed per
day and 25 mg of iron is required daily for erythropoiesis, mostly
obtained from iron recycling.26 As a result of limited iron supply from
macrophage-led iron retention, patients with chronic inflammatory
conditions have greater daily iron requirements to increase the levels
of circulating iron compared with healthy individuals.27–29 As a conse-
quence of severely depleted iron availability, proper functioning of
many organ systems is compromised in these patients.27–29 For exam-
ple, iron content and transferrin receptor levels were decreased in the
myocardium of patients with iron deficiency anemia and advanced
heart failure compared with healthy individuals, suggesting that iron
depletion was associated with adverse outcomes in these patients.30
1.2 | Defining iron deficiency
Based on our literature review, it is evident that iron deficiency is not
fully recognized as a disorder distinct from iron deficiency anemia, or
as one that may have its own clinical consequences. Indeed, the terms
“iron deficiency” and “iron deficiency anemia” are often used inter-
changeably.31 Where iron deficiency is discussed, it is frequently per-
ceived as the most common nutritional disorder worldwide,31–33 but
not as a medical condition in and of itself.34
It is clear that the heterogeneity in how iron deficiency is defined
is a knowledge gap that is compounding physicians’ lack of confidence
in recognizing and diagnosing this condition. The lack of a standard
simple definition for iron deficiency hinders its uncoupling from iron
deficiency anemia and its acceptance as a standalone medical condition
with distinct clinical implications.
1.3 | Expert recommendation
We propose the following wording as an overarching definition of iron
deficiency:
Iron deficiency is a health-related condition in which iron availabil-
ity is insufficient to meet the body’s needs and which can be pres-
ent with or without anemia
1.4 | Clinical impact of iron deficiency
Iron deficiency may contribute to several symptoms that can manifest
even in the absence of progression to anemia. Although there are
symptoms that are likely to be caused by iron deficiency (eg, pagopha-
gia, and RLS), many symptoms are nonspecific, such as fatigue, and
exhaustion.35–38 This means that physicians and patients do not always
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recognize that iron deficiency is present and, as a consequence, diagno-
sis is not pursued and the condition is left untreated.
Physicians may need to actively ask their patients about such
symptoms, especially for those patient populations where iron defi-
ciency is highly prevalent, so that appropriate diagnostic tests can be
performed and, if necessary, treatment can be given.35 In this section,
we outline the iron deficiency symptoms that have been commonly
reported in patients with CHF, CKD and IBD, as well as its associated
clinical outcomes that further call for its prompt diagnosis and
management.
1.5 | Iron deficiency in chronic heart failure
Iron deficiency is estimated to affect between 37 and 61% of patients
living with CHF, and its prevalence increases as CHF advances.5–7,9
The etiology of iron deficiency in CHF is not fully understood, but it is
thought to be multifactorial and arising from: a general loss of appetite
and poor nutrition; decreased gastrointestinal (GI) iron absorption due
to edema; increased GI blood loss that may occur partially as a result of
antiplatelet and anticoagulant drugs; and, importantly, as a conse-
quence of the chronic inflammatory state of these patients.28,39 The
diagnosis of iron deficiency in CHF is complicated by the fact that the
key manifestations of CHF (fatigue, exercise intolerance) are the same
as those of iron deficiency. Fatigue is frequently associated with iron
deficiency in CHF patients and linked with reduced exercise and work
capacity.40–43 In a recent study using the 6-min walk test (6MWT),
exercise-induced symptoms were significantly more frequent in iron-
deficient CHF patients (35%) compared with non-iron-deficient
patients (27%; P50.028); the most commonly reported symptom was
fatigue.44
In CHF, iron deficiency has been shown to adversely impact exer-
cise capacity and QoL independently of anemia. Iron deficiency
FIGURE 1 The pathophysiology of iron deficiency in chronic inflammation. Increased cytokine levels in all conditions, and decreased renal
clearance in CKD and CHF, result in enhanced hepcidin levels. High hepcidin levels bind, internalize and degrade ferroportin on the lateral
membrane of duodenal enterocytes and spleen macrophages. Iron remains trapped in enterocytes, which are then shed in the gut. Iron is
also sequestered into macrophages, which are responsible for destroying senescent red blood cells and recycling their iron. Serum ferritin
levels are regulated by the iron content of macrophages and increase in inflammation (apoferritin as an acute-phase protein). A decrease in
circulating iron leads to lower amounts of iron bound to the iron carrier protein, transferrin, and subsequently to a decline in transferrin sat-
uration and low iron supply to all organs. Furthermore, cytokines may also have negative effects on erythropoietin production in the kidney
and erythroid cell maturation, while also increasing macrophage iron retention. Note that the increased iron losses that can occur in specific
chronic inflammatory conditions are not illustrated here. Plus and minus signs represent increase/enhancement and decrease, respectively.
EPO, erythropoietin; FPN, ferroportin; IL, interleukin; TNF, tumor necrosis factor; TSAT, transferrin saturation
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significantly reduces exercise tolerance as measured by the
6MWT.17,44–46 In the FAIR-HF study, iron-deficient CHF patients who
were treated for iron deficiency with intravenous (IV) iron, ferric car-
boxymaltose, had significant improvements in the 6MWT (P<0.001 at
weeks 4, 12, and 24) compared with those receiving placebo.45 These
findings are supported in the recent EFFECT-HF study, whereby treat-
ment with ferric carboxymaltose led to significant improvement in
exercise capacity in iron-deficient CHF patients compared with other
standard treatments other than IV iron.47 In a secondary analysis, the
same patients experienced significantly increased QoL as measured by
the Kansas City Cardiomyopathy questionnaire (P<0.001).45 Studies
demonstrated that QoL was significantly affected by iron deficiency in
patients with CHF, whether assessed using the European Quality of
Life-5D, Kansas City Cardiomyopathy or the Minnesota Living with
Heart Failure questionnaires.17,48,49
Iron deficiency can also negatively impact outcomes in CHF. The
increased risk of mortality from iron deficiency in studies evaluating
CHF patients ranges between 40 and 60%.5–7 Iron deficiency in CHF
has also been associated with increased hospitalizations, with one
study showing that the risk of hospitalization doubled in patients who
were not treated for iron deficiency compared with those who were
(relative risk [RR] 2.23, 95% confidence interval [CI] 1.59–3.42,
P<0.01).50 This is further supported by the CONFIRM-HF study,
where treatment of iron deficiency with ferric carboxymaltose was
associated with a significant reduction in hospitalizations (hazard ratio
[HR] 0.39, 95% CI 0.19–0.82, P50.009).46
Notably, the benefit of treating iron deficiency in this setting
occurs whether or not patients are also anemic, thus establishing iron
deficiency as an independent therapeutic target in CHF.51,52 This has
led to compulsory iron deficiency screenings in patients with CHF and
treatment with IV iron (eg, ferric carboxymaltose) has been
recommended.
1.6 | Iron deficiency in chronic kidney disease
The prevalence of iron deficiency in patients with CKD has been
reported as ranging from 24 to 85% and, as for CHF, the prevalence
increases as CKD progresses.4,8 Similar to CHF, iron deficiency in CKD
can arise from decreased GI iron absorption, malnutrition and blood
loss, which is worsened by chronic inflammation.29 Blood loss in CKD
patients can originate from ongoing assessment tests and treatments
such as dialysis. Additionally, iron utilization is promoted during the use
of erythropoiesis-stimulating agents (ESAs). ESA therapy, while effec-
tive in correcting anemia, can further exacerbate iron deficiency, which
in turn may result in poor response to ESAs.53–56 Unlike cardiologists,
nephrologists do not recognize iron deficiency, which is easily treatable,
as a distinct entity and still aim to treat iron deficiency in the context
of anemia management. Thus, in contrast to CHF, where there is
strong evidence that iron deficiency alone impacts the underlying dis-
ease, the evidence in CKD is almost non-existent and focuses only on
anemia, of which iron deficiency is a major cause.
Anemia in CKD is frequently associated with reduced QoL,57 par-
ticularly in physical domains such as vitality and energy.58 Similar to
CHF, these physical domains appear to play a major role in patient
QoL. This is supported by data demonstrating that normalization of
hemoglobin (Hb) levels is associated with significant improvements in
physical function (SF-36 scores; P<0.001).56
At present, the major importance of iron deficiency in CKD is its
role in the development of chronic anemia, which is easily correctable.
Anemia in CKD is associated with an increased risk of morbidity and
mortality.59,60 In non-dialysis CKD patients, lower time-averaged Hb
levels correlated with a significantly increased risk of predialysis mortal-
ity and end-stage renal disease (HR [95% CI] of Hb <11, 11–12 and
12–13 g dL21: 2.57 [1.85–3.58], 1.97 [1.45–2.66], and 1.19 [0.86–
1.63]; all vs. Hb >13 g dL21, Ptrend<0.001).
59 In a 5-year observational
study, anemia in CKD patients was again associated with increased
mortality, regardless of CKD severity.61 The change from baseline to
follow-up in the prevalence of anemia was much higher in patients
with CKD stage 2 and 3 who died (stage 2: 42.1%; stage 3: 42.2%)
compared with those who were alive (stage 2: 24%; stage 3: 28.3%) at
the end of observation.61 Notably, one study demonstrated that ESA
treatment for the correction of anemia in patients with type 2 diabetes
and CKD had significant safety concerns, (eg, stroke).62 Moreover, no
overall cardiovascular, renal or QoL benefits were observed when
targeting higher Hb levels compared with the placebo group,
who received only iron.62 This further supports the point of
treating iron deficiency prior to anemia development and requirement
for ESAs.
Anemia in CKD patients is often associated with cardiovascular
morbidities and can result in increased hospitalization (HR 2.18, CI
1.76–2.70),63 leading to cardio–renal–anemia syndrome. While this
overlap between CKD and CHF populations is recognized, the nature
of cardiac disease may differ between these groups. As there are dif-
ferences in the nature of the heart failure, the consequences and treat-
ment of iron deficiency may also differ.
1.7 | Iron deficiency in inflammatory bowel disease
Iron deficiency affects between 13 and 90% of patients with IBD,
depending on the population that is studied, eg, in- or outpatients,
active or quiescent, as well as severity of the disease.4 The main causes
of iron deficiency in IBD arise from impaired GI iron absorption due to
chronic inflammation, bowel resection (especially in Crohn’s disease),
disease triggered malnutrition and (mainly chronic) blood loss.27 As
with nephrologists, not all gastroenterologists fully appreciate the
importance of managing iron deficiency. This may be because the role
of iron deficiency anemia in IBD is not fully understood—evidence
often depends on the selected patients from tertiary referral centers,
including: Crohn’s disease and ulcerative colitis; hospitalized patients
versus outpatients; or patients with and without surgical interven-
tions.27,64 Iron deficiency can be easily corrected before the onset of
anemia; however, the current evidence base focuses on iron deficiency
anemia and its treatment.22
Iron deficiency anemia is recognized as one of the most common
complications and extra-intestinal manifestations of IBD. However,
over 50% of patients who are diagnosed with iron deficiency anemia
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are not treated.65 In a recent survey, it was shown that approximately
one-third of patients diagnosed with IBD, who are unsure of their ane-
mia status, do not discuss the possibility of developing iron deficiency
anemia with healthcare professionals.22 In this same survey, patients
attributed weakness and chronic fatigue to both IBD and iron defi-
ciency anemia.22 Chronic fatigue associated with iron deficiency ane-
mia may be debilitating and has been suggested to be the primary
cause of impaired QoL in anemic IBD patients, to the same extent as
other symptoms such as abdominal pain and diarrhea.22,27,66 Notably,
improvements in iron status with IV iron treatment have led to signifi-
cantly improved QoL in patients with ulcerative colitis and Crohn’s dis-
ease, according to IBD QoL questionnaire scores (P<0.001) and SF-36
physical (P<0.001) and mental component (P50.024) scores.18 Fur-
thermore, changes in Hb levels (but not the activity of the underlying
disease) were associated with significant changes in SF-36 (P50.005)
and IBD QoL questionnaire (P50.009) scores in IBD patients with iron
deficiency anemia.67
1.8 | Diagnosis of iron deficiency in chronic
inflammatory conditions
Our review of international guidelines available for CHF, CKD and IBD
reveals no consensus practical guidance for diagnosing iron deficiency
independent of anemia (Table 1). However, only some guidelines rec-
ognize iron deficiency as a standalone condition—whether this is
through lack of awareness of iron deficiency or an intentional omission
is difficult to establish (Table 1). Iron deficiency can be simply diag-
nosed with routinely available blood tests measuring serum ferritin and
transferrin saturation (TSAT).86 yet guidelines often lack agreement on
test cut-off values for these parameters.4 Serum ferritin levels are
TABLE 1 Iron deficiency anemia has more guideline coverage than iron deficiency: summary of iron deficiency diagnostic measures, inde-
pendent of anemia68–85
Recommended iron deficiency threshold values independent of anemia
Professional association Year ID/IDAa Serum ferritin (mg L21) TSAT (%) Additional tests
Chronic heart failure
ACCF/AHA 2017 ID and IDA <100 or 100–300 – and <20 –
Canadian Cardiovascular Society 2014 IDA only – – –
European Society of Cardiology 2016 ID and IDA <100 or 100–299 – and <20 –
French cardiologists 2014 ID AID <100; FID 100–299 – and <20 –
German commentary for European
Society of Cardiology
2013 ID <100 or 100–299 – and <20 –
National Heart Foundation of
Australia and Cardiac Society of
Australia and NZ
2011 ID No threshold
recommended
No threshold
recommended
–
Spanish Society of Cardiology and
Spanish Society of Internal Medicine
2017 ID <100 or <20 If patients have SF
<100 mg L21 but
TSAT >20%, test for sTfr
Chronic kidney diseaseb
Canadian Society of Nephrology 2008 IDA only – – –
ERBP 2013 ID and IDA AID <100 and <20 –
KDIGO 2012 IDA only – – –
KDOQI 2012 IDA only – – –
KHA-CARIc 2013 ID <100; <200–500 <20; <20–30
NCGC 2015 IDA only – – –
UK NICE 2015 IDA only – – –
UK Renal Association 2012 IDA only – – –
Inflammatory bowel disease
Quiescent IBD
ECCO 2015 ID and IDA <30 – –
Portuguese Working Group on IBD 2016 ID and IDA <30 and <16 CRP assessments
Active inflammatory bowel disease
British Society of Gastroenterology 2011 ID and IDA <50d – –
ECCO 2015 ID and IDA <100 – –
Portuguese Working Group on IBD 2016 ID and IDA 30–100 and <16 CRP assessments
aGuidelines that only report diagnosis thresholds specific to IDA have been described as ‘IDA only’.
bIncludes both haemodialysis and non-dialysis chronic kidney disease.
cThese threshold values are based on target ranges for the treatment of iron deficiency.
dPossibly more, depending on degree of inflammation. ACCF, American College of Cardiology Foundation; AHA, American Heart Association; AID,
absolute iron deficiency; CRP, C-reactive protein; ECCO, European Crohn’s and Colitis Organisation; ERBP, European Renal Best Practice; FID, func-
tional iron deficiency; IBD, inflammatory bowel disease; ID, iron deficiency; IDA, iron deficiency anemia; KDIGO, Kidney Disease Improving Global Out-
comes; KDOQI, Kidney Disease Outcomes Quality Initiative; KHA-CARI, Kidney Health Australia—Caring for Australasians with Renal Impairment;
NCGC, National Clinical Guideline Centre; NICE, National Institute for Health and Care Excellence; NZ, New Zealand; SF, serum ferritin; sTfr, soluble
transferrin receptor; TSAT, transferrin saturation.
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sensitive to inflammation and some guidelines recommend assessment
of chronic inflammation (according to inflammatory markers such as
C-reactive protein [CRP] and erythrocyte sedimentation rate); however,
there is little consensus for many conditions on when this should be
measured, should it be standard practice for all patients or measured
only when serum ferritin is >30 mg L21 or if patients are sympto-
matic68,87? Moreover, no standard CRP cut-off values are provided;
although a CRP level of 5 mg L21 is the most common threshold,64 this
is not recognized in most guidelines68
1.9 | Expert recommendation
There is little focus in the guidelines on how iron deficiency in the
absence of anemia should be diagnosed in relation to the underlying
chronic disease. Thus, it is of little surprise that physicians may not pri-
oritize iron deficiency treatment. We wish to propose, based on the lit-
erature available, the following consensus laboratory test cut-off values
in patients with CHF, CKD or IBD:
Serum ferritin <100 mg L21 or TSAT <20%
If serum ferritin is between 100 and 300 mg L21, a TSAT test will
be required to confirm iron deficiency
Furthermore, we also propose the following algorithms for the
diagnostic workup of iron deficiency in patients with CHF, CKD, and
IBD (Figures 2–4). In all conditions, initial workup should incorporate
assessment of serum ferritin and TSAT, as well as Hb levels, in order to
distinguish between those with normal hematological parameters, those
with some form of iron deficiency (iron deficiency: normal Hb and low
iron; or iron deficiency anemia: low Hb and low iron), and those with
some other form of anemia (where iron levels are normal but Hb is
low). In CKD, we must also consider whether the patient is receiving
dialysis (Figure 3A,B). Finally, in IBD, we must further consider whether
the underlying condition is in remission or active. For IBD, we therefore
also recommend measuring CRP levels or stool markers such as calpro-
tectin or lactoferrin at the time of iron markers and hematological
workup, in order to appropriately manage iron deficiency in relation to
these results. We recommend a CRP threshold of 5 mg L21 to deter-
mine the IBD disease activity. Although laboratory markers are usually
sufficient with clinical disease activity markers, other indicators of intes-
tinal inflammation, such as transabdominal ultrasound or endoscopy,
may also be used to supplement these assessments.
1.10 | Iron deficiency in high-risk populations with
chronic inflammatory conditions
Chronic conditions cannot be viewed in isolation and there will be cir-
cumstances where individuals may have further increased susceptibilityFIGURE 2 Diagnostic algorithm: iron deficiency in chronic heart
failure. *Look for other causes of anemia and treat accordingly. Hb,
haemoglobin; IV, intravenous; NYHA, New York Heart Association;
SF, serum ferritin; TSAT, transferrin saturation
FIGURE 3 Diagnostic algorithms: iron deficiency in (A) non-
dialysis and (B) dialysis chronic kidney disease. *If iron stores are
normal but Hb is low, look for other causes of anemia and treat
accordingly. **When prescribing ESA therapy, iron should always
be administered. ESA, erythropoiesis-stimulating agent; Hb, haemo-
globin; IV, intravenous; SF, serum ferritin; TSAT, transferrin
saturation
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to iron deficiency. To optimize outcomes for these patients, risks need
to be pre-empted wherever possible. Three important populations to
consider among your patients are: women (particularly those who are
pregnant or are planning to become pregnant, and those who suffer
from heavy menstrual bleeding [HMB]); the elderly; and those under-
going surgery.
Women of reproductive age are one of the most at-risk population
groups for iron deficiency anemia. Between 4 and 52% of women of
reproductive age are reported to suffer from HMB, with a wide range
reflecting disparities between study populations and how HMB is
defined88 Notably, a recent European study demonstrated that 63% of
the participating HMB patients were suffering from iron deficiency or
iron deficiency anemia.89 Iron deficiency in combination with HMB can
have debilitating consequences on the QoL and wellbeing of the
sufferer.90–93 Thus, many of these women enter pregnancy with low
iron stores and are often already anemic. Approximately 42% of preg-
nant women worldwide have anemia, with iron deficiency anemia
being the primary cause, and this may have a serious detrimental effect
on the outcome for both mother and child.2,94–96 In pregnancy, iron
deficiency anemia is associated with increased maternal morbidity and
mortality, possibly due to not being able to withstand the adverse
effect of excessive blood loss at delivery and the increased risk of
infection.96 Iron deficiency anemia also affects the child and has been
linked with increased risk of preterm labor and subsequent low birth-
weight, and perinatal complications.97 Moreover, there is an association
between maternal iron status in pregnancy with that of the infant; with
infants born to anemic mothers being more likely to be anemic them-
selves.98 Iron deficiency also carries negative long-term impact on the
FIGURE 4 Diagnostic algorithm: iron deficiency in inflammatory bowel disease. *Look for other causes of anemia and treat accordingly.
CRP, C-reactive protein; Hb, haemoglobin; IV, intravenous; SF, serum ferritin; TSAT, transferrin saturation
TABLE 2 Benefits and limitations of oral versus intravenous iron20,106–111
Oral iron IV iron
General benefits · Ease of use
· Lower costs compared with IV iron
· More efficient and faster than oral iron at increasing
iron availability and Hb levels
· Effective in the presence of inflammation
· Fewer GI side effects than oral iron
· Few administrations required to reach target serum
ferritin, TSAT and Hb (compared with
daily intake of oral iron)
· IV administration ensures treatment adherence
General limitations · Low intestinal absorption of iron (10–20%)
· Low absorption results in slow and limited efficacy
· Requires daily intake of up to three equally spaced doses
· Decreased iron absorption in inflammatory conditions
· Unfavorable (GI) adverse-event profile
· Low adherence to treatment
· Accidental iron overdose with ferrous salts (eg, ferrous sulfate)a
· Requires medical expertise for administration and
facilities for cardiopulmonary resuscitation
· Potential fatal hypersensitivity may occur
· Side effects at injection site may occur
· More expensive than oral iron
· Complex stability varies between preparations;
less stable complexes release larger amounts of
weakly bound iron in the blood and can induce
oxidative stress if given in high doses
aThe US Food and Drug Administration has issued a black box warning.
GI, gastrointestinal; Hb, hemoglobin; IV, intravenous; TSAT, transferrin saturation.
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mother–child relationship and the child’s cognitive development, of
which the latter has shown to persist for up to 10 years, even after
iron repletion.95,99,100
Extra vigilance should also be taken when managing elderly
patients. The prevalence of iron deficiency increases rapidly with age,
and timely diagnosis and treatment of iron deficiency will substantially
improve outcomes and QoL for a population prone to multiple comor-
bidities.101,102 Where surgery is required for your IBD patients, regard-
less of age, the impact of iron deficiency during procedures that have
the potential to result in major blood loss has to be recognized early
and proactively managed. An awareness of the substantial impact of
pre-operative iron deficiency with and without anemia on morbidity
and mortality is increasing, with growing recognition that patient blood
management procedures need to be established across all surgical
specialties.103–105
1.11 | Management of iron deficiency in chronic
inflammatory conditions
Treatment options for iron deficiency fall into two broad categories,
oral and IV iron preparations. There are advantages and limitations for
each (Table 2) and physicians must decide on the most suitable option
on a patient-by-patient basis. Factors that should be considered are:
the inflammatory condition of the patient; the degree of iron deficit
(ie, the total amount of iron to be replenished); and the time frame that
is available or acceptable to achieve adequate iron stores.
Oral iron treatments are the most widely used, largely because of
convenience, but there are a number of limitations that impact their
effectiveness in patients with chronic inflammatory conditions (Table
2). Oral iron absorption from the ingested amount is low (on average
10%) and even in iron-deficient conditions, upregulation of absorption
may be limited.106 During active inflammation, absorption is further
reduced as a result of hepcidin-mediated ferroportin inhibition.15 Thus,
oral iron supplementation may fail to supply sufficient amounts of iron
in chronic inflammatory conditions. Recent evidence from the IRON-
OUT study further supports the ineffectiveness of oral iron in the
chronic disease setting. In this study, no improvement in exercise toler-
ance or iron stores was demonstrated with oral iron treatment in iron-
deficient patients with CHF.112 In the CKD setting, the proportion of
anemic patients achieving Hb increase of 1 g dL21 at any time was
significantly reduced in the oral iron group compared with the IV iron
group (P<0.001).113 Moreover, oral iron treatment has recently been
associated with significant changes in the normal gut microbiota, add-
ing to our understanding of how oral iron causes its well-known GI tol-
erability profile, which is particularly detrimental to IBD patients.114
The alternative solution, IV iron treatment, can deliver a larger iron
supply, effectively replenishing iron stores more rapidly than oral iron
and, because of the route of administration, bypassing the risk of GI
side effects. Many guidelines acknowledge the benefits of IV iron prep-
arations as a valuable option for patients with chronic inflammatory
diseases who lack a response to, are non-compliant with, or are intoler-
ant of oral iron treatment, as well as those who have severe iron defi-
ciency and require rapid replenishment of available iron and Hb levels.
However, multiple IV iron preparations are available for which the dos-
ing, infusion times, efficacy and safety profiles can vary. While some
products have very little data published demonstrating their benefit-to-
risk profile, for other IV iron preparations, such as ferric carboxymal-
tose, there is a wealth of clinical evidence, including studies in all three
chronic inflammatory conditions within the scope of this review; there
is a growing evidence base supporting its effectiveness and good toler-
ability across patient groups.32,115–117
2 | CONCLUSIONS
Iron deficiency is a very common but often overlooked condition, espe-
cially in patients with chronic inflammatory conditions. It is a highly rel-
evant comorbidity and accounts for poor outcomes, prolonged
hospitalization and poor QoL in this patient population. Here, we have
proposed several practical recommendations for the definition and
diagnosis of iron deficiency in CHF, CKD and IBD. Based on this defini-
tion and diagnosis threshold, simple diagnostic algorithms and manage-
ment for these conditions have been discussed. The intention of these
recommendations is to provide consensus expert opinion where there
is variability in the guidelines or gaps in the current evidence base.
ACKNOWLEDGMENTS
This study was sponsored by Vifor Pharma. Medical writing support
was provided by Mai Kurihara, PhD, from Mudskipper Business Ltd,
funded by Vifor Pharma.
CONFLICTS OF INTEREST
All IRON CORE members have received honoraria as advisors from
Vifor Pharma. WD has also received a grant from Vifor Pharma.
REFERENCES
[1] Henriques C. Vifor supports efforts to make public more aware of
iron deficiency and its health impact (28 November). IBD News
Today 2016. Available at: https://ibdnewstoday.com/2016/11/28/
vifor-pharma-supports-efforts-to-raise-awareness-of-iron-defi-
ciency-in-ibd-patients-others/.
[2] GBD 2015 Disease and Injury Incidence and Prevalence Collabora-
tors. Global, regional, and national incidence, prevalence, and years
lived with disability for 310 diseases and injuries, 1990–2015: a
systematic analysis for the Global Burden of Disease Study 2015.
Lancet. 2016;388:1545–1602.
[3] Nolte E, Knai C, Saltman RB. Assessing chronic disease manage-
ment in European health systems: concepts and approaches. 2014.
Available at: http://www.euro.who.int/en/about-us/partners/
observatory/publications/studies/assessing-chronic-disease-man-
agement-in-european-health-systems-concepts-and-approaches.
[4] Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis
and treatment of iron deficiency across indications: a systematic
review. Am J Clin Nutr. 2015;102:1585–1594.
[5] Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an
ominous sign in patients with systolic chronic heart failure. Eur
Heart J. 2010;31:1872–1880.
8 | AJH CAPPELLINI ET AL.
[6] Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic
heart failure: an international pooled analysis. Am Heart J. 2013;
165:575–582.
[7] Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disor-
dered iron homeostasis in chronic heart failure: prevalence, predic-
tors, and relation to anemia, exercise capacity, and survival. J Am
Coll Cardiol. 2011;58:1241–1251.
[8] McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of ane-
mia in patients with chronic kidney disease. Curr Med Res Opin.
2004;20:1501–1510.
[9] Yeo TJ, Yeo PS, Ching-Chiew WR, et al. Iron deficiency in a multi-
ethnic Asian population with and without heart failure: prevalence,
clinical correlates, functional significance and prognosis. Eur J Heart
Fail. 2014;16:1125–1132.
[10] Wessling-Resnick M. Iron homeostasis and the inflammatory
response. Annu Rev Nutr. 2010;30:105–122.
[11] Wang J, Pantopoulos K. Regulation of cellular iron metabolism.
Biochem J. 2011;434:365–381.
[12] Macdougall IC, Canaud B, de Francisco AL, et al. Beyond the cardi-
orenal anaemia syndrome: recognizing the role of iron deficiency.
Eur J Heart Fail. 2012;14:882–886.
[13] Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron defi-
ciency anaemia. Lancet. 2016;387:907–916.
[14] Kassebaum NJ. The global burden of anemia. Hematol Oncol Clin
North Am. 2016;30:247–308.
[15] Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721–1741.
[16] Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeu-
tic target in anemias and iron overload disorders. Hematology Am
Soc Hematol Educ Program. 2011;2011:538–542.
[17] Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the
treatment of chronic heart failure and iron deficiency: systematic
review and meta-analysis. Eur J Heart Fail. 2012;14:423–429.
[18] Cekic C, Ipek S, Aslan F, et al. The effect of intravenous iron treat-
ment on quality of life in inflammatory bowel disease patients
with nonanemic iron deficiency. Gastroenterol Res Pract. 2015;
2015:582163.
[19] Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:
1832–1843.
[20] Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med.
2005;352:1011–1023.
[21] Weiss G. Anemia of chronic disorders: new diagnostic tools and
new treatment strategies. Semin Hematol. 2015;52:313–320.
[22] Danese S, Hoffman C, Vel S, et al. Anaemia from a patient per-
spective in inflammatory bowel disease: results from the European
Federation of Crohn’s and Ulcerative Colitis Association’s online
survey. Eur J Gastroenterol Hepatol. 2014;26:1385–1391.
[23] Himmelfarb J. Iron regulation. J Am Soc Nephrol. 2007;18:379–381.
[24] Ganz T. Iron in innate immunity: starve the invaders. Curr Opin
Immunol. 2009;21:63–67.
[25] Cherayil BJ. The role of iron in the immune response to bacterial
infection. Immunol Res. 2011;50:1–9.
[26] Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts:
molecular control of mammalian iron metabolism. Cell. 2004;117:
285–297.
[27] Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflam-
matory bowel diseases. Gut. 2004;53:1190–1197.
[28] Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency
and heart failure: diagnostic dilemmas and therapeutic perspec-
tives. Eur Heart J. 2013;34:816–829.
[29] Tsagalis G. Renal anemia: a nephrologist’s view. Hippokratia. 2011;
15:39–43.
[30] Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial
and systemic iron depletion in heart failure implications for anemia
accompanying heart failure. J Am Coll Cardiol. 2011;58:474–480.
[31] World Health Organization. Iron deficiency anaemia. Assessment,
prevention and control: a guide for programme managers. 2001.
Available at: http://whqlibdoc.who.int/hq/2001/WHO_NHD_01.3.
pdf.
[32] Keating GM. Ferric carboxymaltose: a review of its use in iron
deficiency. Drugs. 2015;75:101–127.
[33] von Haehling S, Jankowska EA, van Veldhuisen DJ, et al. Iron defi-
ciency and cardiovascular disease. Nat Rev Cardiol. 2015;12:659–669.
[34] Pratt JJ, Khan KS. Non-anaemic iron deficiency—a disease looking
for recognition of diagnosis: a systematic review. Eur J Haematol.
2016;96:618–628.
[35] Koduru P, Abraham BP. The role of ferric carboxymaltose in the
treatment of iron deficiency anemia in patients with gastrointesti-
nal disease. Therap Adv Gastroenterol. 2016;9:76–85.
[36] Goldberg ND. Iron deficiency anemia in patients with inflammatory
bowel disease. Clin Exp Gastroenterol. 2013;6:61–70.
[37] Borgna-Pignatti C, Zanella S. Pica as a manifestation of iron defi-
ciency. Expert Rev Hematol. 2016;9:1075–1080.
[38] Trenkwalder C, Allen R, Hogl B, et al. Restless legs syndrome asso-
ciated with major diseases: a systematic review and new concept.
Neurology. 2016;86:1336–1343.
[39] McDonagh T, Macdougall IC. Iron therapy for the treatment of
iron deficiency in chronic heart failure: intravenous or oral?. Eur J
Heart Fail. 2015;17:248–262.
[40] Brownlie T, Utermohlen V, Hinton PS, et al. Marginal iron defi-
ciency without anemia impairs aerobic adaptation among previ-
ously untrained women. Am J Clin Nutr. 2002;75:734–742.
[41] Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a
critical review of the research to determine a causal relationship.
J Nutr. 2001;131:676S–688S.
[42] Jankowska EA, Malyszko J, Ardehali H, et al. Iron status in patients
with chronic heart failure. Eur Heart J. 2013;34:827–834.
[43] Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency
predicts impaired exercise capacity in patients with systolic chronic
heart failure. J Card Fail. 2011;17:899–906.
[44] Enjuanes C, Bruguera J, Grau M, et al. Iron status in chronic heart
failure: impact on symptoms, functional class and submaximal exer-
cise capacity. Rev Esp Cardiol (Engl Ed). 2016;69:247–255.
[45] Anker SD, Comin CJ, Filippatos G, et al. Ferric carboxymaltose in
patients with heart failure and iron deficiency. N Engl J Med. 2009;
361:2436–2448.
[46] Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial
effects of long-term intravenous iron therapy with ferric carboxy-
maltose in patients with symptomatic heart failure and iron defi-
ciencydagger. Eur Heart J. 2015;36:657–658.
[47] van Veldhuisen DJ, Ponikowski P, Metra M, et al. Effect of Ferric
Carboxymaltose on Exercise Capacity in Patients with Iron Deficiency
and Chronic Heart Failure (EFFECT-HF): a Randomized, Controlled
Study (NCT01394562). New Orleans, LA, USA: American Heart
Association 2016 Scientific Sessions; 2016.
[48] Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Rationale and
design of the CONFIRM-HF study: a double-blind, randomized,
placebo-controlled study to assess the effects of intravenous ferric
carboxymaltose on functional capacity in patients with chronic heart
failure and iron deficiency. ESC Heart Failure. 2014;1:52–58.
CAPPELLINI ET AL. AJH | 9
[49] Enjuanes C, Klip IT, Bruguera J, et al. Iron deficiency and health-
related quality of life in chronic heart failure: results from a multi-
center European study. Int J Cardiol. 2014;174:268–275.
[50] Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron
reduces NT-pro-brain natriuretic peptide in anemic patients with
chronic heart failure and renal insufficiency. J Am Coll Cardiol.
2007;50:1657–1665.
[51] Filippatos G, Farmakis D, Colet JC, et al. Intravenous ferric carbox-
ymaltose in iron-deficient chronic heart failure patients with and
without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart
Fail. 2013;15:1267–1276.
[52] Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intrave-
nous iron therapy in iron-deficient patients with systolic heart fail-
ure: a meta-analysis of randomized controlled trials. Eur J Heart
Fail. 2016;18:786–795.
[53] Horl WH. Non-erythropoietin-based anaemia management in chronic
kidney disease. Nephrol Dial Transplant. 2002;17(Suppl 11):35–38.
[54] Wish JB. Assessing iron status: beyond serum ferritin and transfer-
rin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl 1):S4–S8.
[55] Leaf DE, Goldfarb DS. Interpretation and review of health-related
quality of life data in CKD patients receiving treatment for anemia.
Kidney Int. 2009;75:15–24.
[56] Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglo-
bin level in patients with chronic kidney disease and anemia. N
Engl J Med. 2006;355:2071–2084.
[57] Dowling TC. Prevalence, etiology, and consequences of anemia
and clinical and economic benefits of anemia correction in patients
with chronic kidney disease: an overview. Am J Health Syst Pharm.
2007;64:S3–S7.
[58] Finkelstein FO, Story K, Firanek C, et al. Health-related quality of
life and hemoglobin levels in chronic kidney disease patients. Clin J
Am Soc Nephrol. 2009;4:33–38.
[59] Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Associa-
tion of anemia with outcomes in men with moderate and severe
chronic kidney disease. Kidney Int. 2006;69:560–564.
[60] Singh AK, Szczech L, Tang KL, et al. Correction of anemia with
epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:
2085–2098.
[61] Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and
outcomes among a population with chronic kidney disease in a large
managed care organization. Arch Intern Med. 2004;164:659–663.
[62] Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin
alfa in type 2 diabetes and chronic kidney disease. N Engl J Med.
2009;361:2019–2032.
[63] Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortal-
ity, cardiovascular hospitalizations and end-stage renal disease
among patients with chronic kidney disease. Nephrology (Carlton).
2009;14:240–246.
[64] Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease:
a neglected issue with relevant effects. World J Gastroenterol.
2014;20:3542–3551.
[65] Ott C, Liebold A, Takses A, et al. High prevalence but insufficient
treatment of iron-deficiency anemia in patients with inflammatory
bowel disease: results of a population-based cohort. Gastroenterol
Res Pract. 2012;2012:595970.
[66] Jelsness-Jorgensen LP, Bernklev T, Henriksen M, et al. Chronic
fatigue is more prevalent in patients with inflammatory bowel disease
than in healthy controls. Inflamm Bowel Dis. 2011;17:1564–1572.
[67] Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in
hemoglobin level on quality of life and cognitive function in
inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:
123–130.
[68] Dignass AU, Gasche C, Bettenworth D, et al. European consensus
on the diagnosis and management of iron deficiency and anaemia
in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.
[69] KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney
Disease. Kidney Int. 2012;2:279–335.
[70] NICE. Anaemia management in people with chronic kidney dis-
ease. 2015. Available at: www.nice.org.uk/guidance/ng8.
[71] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure: the
Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Devel-
oped with the special contribution of the Heart Failure Association
(HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
[72] Cohen-Solal A, Leclercq C, Mebazaa A, et al. Diagnosis and treat-
ment of iron deficiency in patients with heart failure: expert posi-
tion paper from French cardiologists. Arch Cardiovasc Dis. 2014;
107:563–571.
[73] Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis
and management of iron deficiency and anemia in inflammatory
bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.
[74] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA
focused update of the 2013 ACCF/AHA guideline for the man-
agement of heart failure: a report of the American College of
Cardiology/American Heart association task force on clinical
practice guidelines and the heart failure society of America.
J Card Fail. 2017. doi: 10.1016/j.cardfail.2017.04.014. [Epub
ahead of print]
[75] National Clinical Guideline Centre (NCGC). Anaemia management
in chronic kidney disease. NG8 (update). Commissioned by the
National Institute for Health and Care Excellence. 2015. Available
at: https://www.nice.org.uk/guidance/ng8/evidence/full-guideline-
70545133.
[76] Mikhail A, Shrivastava R, Richardson D. Clinical Practice Guidelines:
Anemia of CKD. 5th ed., 2009–2012. UK: Renal Association; 2012.
[77] Magro F, Ramos J, Correia L, et al. Portuguese consensus on the
diagnosis, prevention and treatment of anemia in inflammatory
bowel disease. Acta Med Port. 2016;29:144–156.
[78] Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for
the management of iron deficiency anaemia. Gut. 2011;60:1309–
1316.
[79] Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the man-
agement of chronic kidney disease. CMAJ. 2008;179:1154–1162.
[80] Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary
on the 2012 KDIGO clinical practice guideline for anemia in CKD.
Am J Kidney Dis. 2013;62:849–859.
[81] Locatelli F, Barany P, Covic A, et al. Kidney disease: improving
global outcomes guidelines on anaemia management in chronic
kidney disease: a European Renal Best Practice position statement.
Nephrol Dial Transplant. 2013;28:1346–1359.
[82] Manito N, Cerqueiro JM, Comin-Colet J, et al. Consensus docu-
ment of the Spanish Society of Cardiology and the Spanish Society
of Internal Medicine on the diagnosis and treatment of iron defi-
ciency in heart failure. Rev Clin Esp. 2017;217:35–45.
[83] Macginley R, Walker R, Irving M. KHA-CARI guideline: use of iron
in chronic kidney disease patients. Nephrology (Carlton). 2013;18:
747–749.
[84] Hasenfuss G, Anker S, Bauersachs J, et al. Kommentar zu den Lei-
tlinien der Europäischen Gesellschaft f€ur Kardiologie (ESC) zur
10 | AJH CAPPELLINI ET AL.
Diagnostik und Behandlung der akuten und chronischen Herzinsuf-
fizienz]. Kardiologe. 2013;7:105–114. [
[85] Krum H, Jelinek MV, Stewart S, et al. 2011 update to National
Heart Foundation of Australia and Cardiac Society of Australia and
New Zealand Guidelines for the prevention, detection and man-
agement of chronic heart failure in Australia, 2006. Med J Aust.
2011;194:405–409.
[86] Polin V, Coriat R, Perkins G, et al. Iron deficiency: from diagnosis
to treatment. Dig Liver Dis. 2013;45:803–809.
[87] Mowat C, Cole A, Windsor A, et al. Guidelines for the manage-
ment of inflammatory bowel disease in adults. Gut. 2011;60:571–
607.
[88] Fraser IS, Langham S, Uhl-Hochgraeber K. Health-related quality
of life and economic burden of abnormal uterine bleeding. Expert
Rev Obstet Gynecol. 2009;4:179–189.
[89] Fraser IS, Mansour D, Breymann C, et al. Prevalence of heavy
menstrual bleeding and experiences of affected women in a Euro-
pean patient survey. Int J Gynaecol Obstet. 2015;128:196–200.
[90] Brownlie T, Utermohlen V, Hinton PS, Haas JD. Tissue iron defi-
ciency without anemia impairs adaptation in endurance capacity
after aerobic training in previously untrained women. Am J Clin
Nutr. 2004;79:437–443.
[91] Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cogni-
tive effects of iron supplementation in non-anaemic iron-deficient
adolescent girls. Lancet. 1996;348:992–996.
[92] Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review
evaluating health-related quality of life, work impairment, and
health-care costs and utilization in abnormal uterine bleeding.
Value Health. 2007;10:183–194.
[93] Verdon F, Burnand B, Stubi CL, et al. Iron supplementation for
unexplained fatigue in non-anaemic women: double blind rando-
mised placebo controlled trial. BMJ. 2003;326:1124.
[94] World Health Organization. Worldwide prevalence of anaemia
1993–2005: WHO Global Database on Anaemia. 2008.
Available at: http://apps.who.int/iris/bitstream/10665/43894/1/
9789241596657_eng.pdf.
[95] Corwin EJ, Murray-Kolb LE, Beard JL. Low hemoglobin level is a risk
factor for postpartum depression. J Nutr. 2003;133:4139–4142.
[96] Cantwell R, Clutton-Brock T, Cooper G, et al. Saving mothers’ lives:
reviewing maternal deaths to make motherhood safer: 2006–2008.
The Eighth Report of the Confidential Enquiries into Maternal
Deaths in the United Kingdom. BJOG. 2011;118(Suppl 1):1–203.
[97] Scholl TO, Hediger ML, Fischer RL, Shearer JW. Anemia vs iron
deficiency: increased risk of preterm delivery in a prospective
study. Am J Clin Nutr. 1992;55:985–988.
[98] Colomer J, Colomer C, Gutierrez D, et al. Anaemia during preg-
nancy as a risk factor for infant iron deficiency: report from the
Valencia Infant Anaemia Cohort (VIAC) study. Paediatr Perinat Epi-
demiol. 1990;4:196–204.
[99] Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in
infancy and low socioeconomic status: a longitudinal analysis of
cognitive test scores to age 19 years. Arch Pediatr Adolesc Med.
2006;160:1108–1113.
[100] Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in
infancy is associated with altered neural correlates of recognition
memory at 10 years. J Pediatr. 2012;160:1027–1033.
[101] Kamangar F, Dores GM, Anderson WF. Patterns of cancer inci-
dence, mortality, and prevalence across five continents: defining
priorities to reduce cancer disparities in different geographic
regions of the world. JCO.2006;24:2137–2150.
[102] Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol
Hemoter. 2016;38:325–330.
[103] Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia
and postoperative outcomes in non-cardiac surgery: a retrospec-
tive cohort study. Lancet. 2011;378:1396–1407.
[104] Munoz M, Acheson AG, Auerbach M, et al. International consen-
sus statement on the peri-operative management of anaemia and
iron deficiency. Anaesthesia. 2017;72:233–247.
[105] National Institute for Health and Care Excellence. Blood transfu-
sion: qs138. 2016. Available at: https://www.nice.org.uk/guid-
ance/qs138.
[106] Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-
deficiency anemia in adults. Am J Med. 2008;121:943–948.
[107] Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a
review of its use in iron-deficiency anemia. Drugs. 2009;69:739–
756.
[108] Morris CC. Pediatric iron poisonings in the United States. South
Med J. 2000;93:352–358.
[109] Geisser P, Burckhardt S. The pharmacokinetics and pharmacody-
namics of iron preparations. Pharmaceutics. 2011;3:12–33.
[110] Aapro M, Osterborg A, Gascon P, et al. Anaemia and cancer: oral
or intravenous iron? 2012. Available at: http://orbi.ulg.ac.be/bit-
stream/2268/153165/1/288.pdf.
[111] Qunibi WY. The efficacy and safety of current intravenous iron
preparations for the management of iron-deficiency anaemia: a
review. Arzneimittelforschung. 2010;60:399–412.
[112] Lewis GD, Anstrom KJ, McNulty S, et al. Oral Iron Repletion
Effects on Oxygen UpTake in Heart Failure (IRONOUT HF). New
Orleans, LA, USA: American Heart Association 2016 Scientific
Sessions; 2016.
[113] Qunibi WY, Martinez C, Smith M, et al. A randomized controlled
trial comparing intravenous ferric carboxymaltose with oral iron
for treatment of iron deficiency anaemia of non-dialysis-
dependent chronic kidney disease patients. Nephrol Dial Transplant.
2011;26:1599–1607.
[114] Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron
replacement therapy distinctly alters the gut microbiota and
metabolome in patients with IBD. Gut. 2016;66:863–871
[115] Breymann C, Milman N, Mezzacasa A, et al. Ferric carboxymaltose
vs. oral iron in the treatment of pregnant women with iron defi-
ciency anemia: an international, open-label, randomized controlled
trial (FER-ASAP). J Perinat Med. 2017;45:443–453.
[116] Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial
comparing ferric carboxymaltose and iron sucrose for treatment of
iron deficiency anemia due to abnormal uterine bleeding. Int J
Gynaecol Obstet. 2016;133:43–48.
[117] Borstlap WA, Buskens CJ, Tytgat KM, et al. Multicentre random-
ized controlled trial comparing ferric(III)carboxymaltose infusion
with oral iron supplementation in the treatment of preoperative
anaemia in colorectal cancer patients. BMC Surg. 2015;15:78.
How to cite this article: Cappellini MD, Comin-Colet J, de Fran-
cisco A, et al. Iron deficiency across chronic inflammatory condi-
tions: International expert opinion on definition, diagnosis, and
management. Am J Hematol. 2017;00:1–11. https://doi.org/10.
1002/ajh.24820
CAPPELLINI ET AL. AJH | 11
